

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1

(43) International Publication Date
18 December 2003 (18.12.2003)

(10) International Publication Number
WO 03/104223 A1

PCT

(51) **International Patent Classification⁷:** C07D 403/04, 401/14, 405/14, C07F 9/02

(21) **International Application Number:** PCT/US03/17906

(22) **International Filing Date:** 5 June 2003 (05.06.2003)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
60/386,415 5 June 2002 (05.06.2002) US

(71) **Applicant (for all designated States except US):** PHARMACIA CORPORATION [Stateless/---]; A Corporation of the State of Delaware, P.O. Box 1027, Chesterfield, MO 63006 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only):** BENSON, Alan, G. [US/US]; 140 BRIGHTHURST Drive, Chesterfield, MO 63005 (US). FRAHER, Thomas, Phillip [US/US]; 2100 West Huron Street, Chicago, IL 60612 (US). HEPPERLE, Michael, E. [DE/US]; 75 Clarendon Street, Apt. 208, Boston, MA 02116 (US). JEROME, Kevin, D. [US/US]; 2339 Pheasant Run Drive, Maryland Heights, MO 63043 (US). NAING, Win [MM/US]; 1198 Noonung Tree Drive, Chesterfield, MO 63017 (US). SELNESS, Shaun, Raj [US/US]; 1875 Cedarhill Drive, Chesterfield, MO 63017 (US).

(US). WALKER, John, K. [US/US]; 11946 Autumn Lakes Drive, Maryland Heights, MO 63043 (US).

(74) **Agents:** GRYTE, David, M. et al.; Harness, Dickey & Pierce, P.L.C., 7700 Bonhomme, Suite 400, St. Louis, MO 63105 (US).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS



(S7) Abstract: This invention is directed generally to pyrazoles that, *inter alia*, inhibit p38 kinase, TNF, and/or cyclooxygenase-2 activity. Such pyrazoles include compounds generally corresponding in structure to the following formula (I), wherein L¹, L², X¹, X², X³, X⁴, X⁵, X⁶, R¹, R^{3A}, R^{3B}, R^{3C}, R⁴, and R⁵ are as defined in this specification. The pyrazoles further include tautomers of such compounds, as well as salts of such compounds and tautomers. This invention also is directed to compositions of such pyrazoles, intermediates for the syntheses of such pyrazoles, methods for making such pyrazoles, and methods for treating (including preventing) conditions (particularly pathological conditions) associated with p38 kinase, TNF, and/or cyclooxygenase-2 activity.

WO 03/104223 A1

PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS

FIELD OF THE INVENTION

[1] This invention is directed to pyrazole compounds (including tautomers of the compounds, and salts of the compounds and tautomers) that, *inter alia*, generally tend to inhibit p38 kinase (particularly p38 α kinase), TNF (particularly TNF- α), and/or cyclooxygenase (particularly cyclooxygenase-2 or "COX-2") activity. This invention also is directed to compositions of such pyrazoles (particularly pharmaceutical compositions), intermediates for the syntheses of such pyrazoles, methods for making such pyrazoles, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

BACKGROUND OF THE INVENTION

[2] Mitogen-activated protein kinases (MAP) constitute a family of proline-directed serine/threonine kinases that activate their substrates by dual phosphorylation. The kinases are activated by a variety of signals, including nutritional and osmotic stress, UV light, growth factors, endotoxin, and inflammatory cytokines. The p38 MAP kinase group is a MAP family of various isoforms, including p38 α , p38 β , and p38 γ . These kinases are responsible for phosphorylating and activating transcription factors (*e.g.*, ATF2, CHOP, and MEF2C), as well as other kinases (*e.g.*, MAPKAP-2 and MAPKAP-3). The p38 isoforms are activated by bacterial lipopolysaccharide, physical and chemical stress, and pro-inflammatory cytokines, including tumor necrosis factor ("TNF") and interleukin-1 ("IL-1"). The products of the p38 phosphorylation mediate the production of inflammatory cytokines, including TNF, IL-1, and cyclooxygenase-2.

[3] It is believed that p38 α kinase can cause or contribute to the effects of, for example, inflammation generally; arthritis; neuroinflammation; pain; fever; pulmonary disorders; cardiovascular diseases; cardiomyopathy; stroke; ischemia; reperfusion injury; renal reperfusion injury; brain edema; neurotrauma and brain trauma; neurodegenerative disorders; central nervous system disorders; liver disease and nephritis; gastrointestinal conditions; ulcerative diseases; ophthalmic diseases; ophthalmological conditions; glaucoma; acute injury to the eye tissue and ocular traumas; diabetes; diabetic

nephropathy; skin-related conditions; viral and bacterial infections; myalgias due to infection; influenza; endotoxic shock; toxic shock syndrome; autoimmune disease; bone resorption diseases; multiple sclerosis; disorders of the female reproductive system; pathological (but non-malignant) conditions, such as hemangiomas, angiofibroma of the nasopharynx, and avascular necrosis of bone; benign and malignant tumors/neoplasia including cancer; leukemia; lymphoma; systemic lupus erythematosus (SLE); angiogenesis including neoplasia; and metastasis.

[4] TNF is a cytokine produced primarily by activated monocytes and macrophages. Excessive or unregulated TNF production (particularly TNF- α) has been implicated in mediating a number of diseases. It is believed, for example, that TNF can cause or contribute to the effects of inflammation (*e.g.*, rheumatoid arthritis and inflammatory bowel disease), asthma, autoimmune disease, graft rejection, multiple sclerosis, fibrotic diseases, cancer, fever, psoriasis, cardiovascular diseases (*e.g.*, post-ischemic reperfusion injury and congestive heart failure), pulmonary diseases (*e.g.*, hyperoxic alveolar injury), hemorrhage, coagulation, radiation damage, and acute phase responses like those seen with infections and sepsis and during shock (*e.g.*, septic shock and hemodynamic shock). Chronic release of active TNF can cause cachexia and anorexia. And TNF can be lethal.

[5] TNF also has been implicated in infectious diseases. These include, for example, malaria, mycobacterial infection, meningitis. These also include viral infections, such as HIV, influenza virus, and herpes virus, including herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus, human herpesvirus-6 (HHV-6), human herpesvirus-7 (HHV-7), human herpesvirus-8 (HHV-8), pseudorabies and rhinotracheitis, among others.

[6] IL-8 is another pro-inflammatory cytokine, which is produced by mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. This cytokine is associated with conditions including inflammation.

[7] IL-1 is produced by activated monocytes and macrophages, and is involved in inflammatory responses. IL-1 plays a role in many pathophysiological responses, including rheumatoid arthritis, fever, and reduction of bone resorption.

[8] TNF, IL-1, and IL-8 affect a wide variety of cells and tissues, and are important inflammatory mediators of a wide variety of conditions. The inhibition of these cytokines by inhibition of the p38 kinase is beneficial in controlling, reducing, and alleviating many of these disease states.

5 [9] Various pyrazoles have previously been described:

[10] In U.S. Patent No. 4,000,281, Beiler and Binon report 4,5-aryl/heteroaryl substituted pyrazoles with antiviral activity against both RNA and DNA viruses, such as myxoviruses, adenoviruses, rhinoviruses, and various viruses of the herpes group.

[11] WIPO Int'l Publ. No. WO 92/19615 (published November 12, 1992)
10 describes pyrazoles as novel fungicides.

[12] In U. S. Patent No. 3,984,431, Cueremy and Renault report derivatives of pyrazole-5-acetic acid as having anti-inflammatory activity, with [1-isobutyl-3,4-diphenyl-1H-pyrazol-5-yl]acetic acid being specifically described.

[13] In U. S. Patent No. 3,245,093, Hinsgen et al report a process for preparing
15 pyrazoles.

[14] WIPO Int'l Publ. No. WO 83/00330 (published February 3, 1983) describes a process for preparing diphenyl-3,4-methyl-5-pyrazole derivatives.

[15] WIPO Int'l Publ. No. WO 95/06036 (published March 2, 1995 reports a process for preparing pyrazole derivatives.

20 [16] In U.S. patent 5,589,439, T. Goto, et al. report tetrazole derivatives and their use as herbicides.

[17] EP 515,041 reports pyrimidinyl substituted pyrazole derivatives as novel agricultural fungicides.

[18] Japanese Patent 4,145,081 reports pyrazolecarboxylic acid derivatives as
25 herbicides.

[19] Japanese Patent 5,345,772 reports novel pyrazole derivatives as inhibiting acetylcholinesterase.

[20] Pyrazoles have been reported as useful in treating inflammation.

[21] Japanese Patent 5,017,470 reports synthesis of pyrazole derivatives as anti-
30 inflammatory, anti-rheumatic, anti-bacterial, and anti-viral drugs.

[22] EP 115640 (published Dec 30, 1983) reports 4-imidazolyl-pyrazole derivatives as inhibitors of thromboxane synthesis, with 3-(4-Isopropyl-1-methylcyclohex-1-yl)-4-(imidazol-1-yl)-1H-pyrazole being specifically described.

[23] WIPO Int'l Publ. No. WO 97/01551 (published Jan 16, 1997) reports
5 pyrazole compounds as adenosine antagonists, with 4-(3-Oxo-2,3-dihydropyridazin-6-yl)-3-phenylpyrazole being specifically described.

[24] In U.S. Patent No. 5,134,142, Matsuo et al. report 1,5-diaryl pyrazoles as having anti-inflammatory activity.

[25] In U.S. Patent No. 5,559,137, Adams et al. report pyrazoles (1,3,4,-
10 substituted) as inhibitors of cytokines used in the treatment of cytokine diseases, with 3-(4-fluorophenyl)-1-(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole being specifically described.

[26] WIPO Int'l Publ. No. WO 96/03385 (published February 8, 1996) reports
3,4-substituted pyrazoles as having anti-inflammatory activity, with 3-
15 methylsulfonylphenyl-4-aryl-pyrazoles and 3-aminosulfonylphenyl-4-aryl-pyrazoles being specifically described.

[27] Laszlo et al., *Bioorg. Med. Chem. Letters*, 8 (1998) 2689-2694, describes certain furans, pyrroles, and pyrazolones (particularly 3-pyridyl-2,5-diaryl-pyrroles) as inhibitors of p38 kinase.

[28] WIPO Int'l Publ. No. WO 98/52940 (PCT Patent Application No.
20 US98/10436 published on November 26, 1998) reports pyrazoles, compositions containing those pyrazoles, and methods for treating p38-mediated disorders using those pyrazoles.


[29] WIPO Int'l Publ. No. WO 00/31063 (PCT Patent Application No.
US99/26007 published on June 2, 2000) also reports pyrazoles, compositions containing
25 those pyrazoles, and methods for treating p38-mediated disorders using those pyrazoles.

[30] In view of the importance of pyrazoles in the treatment of several pathological conditions (particularly those associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity), there continues to be a need for pyrazole compounds exhibiting an improved safety profile, solubility, and/or potency. The
30 following disclosure describes pyrazole compounds that tend to exhibit one or more such desirable qualities.

SUMMARY OF THE INVENTION

[31] This invention is directed to pyrazole compounds that tend to inhibit p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity. This invention also is directed to, for example, a method for inhibiting p38 kinase, TNF, and/or cyclooxygenase-2 activity, and particularly to a method for treating a condition (typically a pathological condition) mediated by p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity. Such a method is typically suitable for use with mammals, such as humans, other primates (*e.g.*, monkeys, chimpanzees. *etc.*), companion animals (*e.g.*, dogs, cats, horses. *etc.*), farm animals (*e.g.*, goats, sheep, pigs, cattle, *etc.*), laboratory animals (*e.g.*, mice, rats, *etc.*), and wild and zoo animals (*e.g.*, wolves, bears, deer, *etc.*).

[32] Briefly, therefore, this invention is directed, in part, to compounds that generally fall within structure of Formula I:



15 This invention also is directed to tautomers of such compounds, as well as salts (particularly pharmaceutically-acceptable salts) of such compounds and tautomers.

[33] In Formula (I):

[34] L^1 is a bond, -O-, -S-, -S(O)-, -S(O)₂-, -N(R^a)-, -C(O)-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -C(O)-O-, -O-C(O)-, -O-C(O)-O-, -C(H)=C(H)-, -C≡C-, -N=N-,
 20 -N(R^a)-N(R^a)-, -N(R^a)-C(O)-N(R^a)-, -C(S)-N(R^a)-, -N(R^a)-C(S)-, -CH₂-, -O-CH₂-, -CH₂-O-, -S-CH₂-, or -CH₂-S-.

[35] X^1 is nitrogen or carbon bonded to hydrogen, except that X^1 is carbon bonded to hydrogen if any of X^2 , X^3 , X^5 , or X^6 is -NH- or -O-.

[36] X^2 is -CH₂-, -NH-, or -O-, except that X^2 is -CH₂- if X^3 is -O- or -NH-.

25 [37] X^3 is -CH₂-, -NH-, or -O-, except that X^3 is -CH₂- if X^2 is -O- or -NH-.

[38] X^4 is nitrogen or carbon bonded to hydrogen.

[39] X^5 is -CH₂- or -NH-, except that X^5 is -CH₂- if X^3 is -O- or X^6 is -NH-.

[40] X^6 is $-CH_2-$ or $-NH-$, except that X^6 is $-CH_2-$ if X^2 is $-O-$ or X^5 is $-NH-$.

[41] R^1 is hydrogen, hydroxyalkyl, carboxyalkyl, aminoalkyl, aminocarbonylalkyl, or aminocarbonylaminoalkyl. The amino nitrogen(s) of the aminoalkyl, aminocarbonylalkyl, or aminocarbonylaminoalkyl optionally is/are substituted
5 with up to two independently selected alkyl.

[42] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected
10 from the group consisting of halogen, hydroxy, and cyano.

[43] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected
15 from the group consisting of halogen, hydroxy, and cyano.

[44] R^{3C} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting
20 of halogen, hydroxy, and cyano.

[45] R^4 is pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any
25 such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclylloxy, carbocyclylalkoxy, carbocyclylloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl,
30 heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocyclylloxy, heterocyclylalkoxy, amino,

aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocyclyloxy carbonyl, heterocyclyloxy carbonyl, alkoxycarbonylamino, alkoxycarbocyclylamino, 5 alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, 10 alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl. Any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclyloxy, heterocyclyl, and 15 heterocyclylalkoxy.

[46] L^2 is a bond, -O-, -S-, -S(O)-, -S(O)₂-, -N(R^a)-, -C(O)-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -C(O)-O-, -O-C(O)-, -O-C(O)-O-, -C(H)=C(H)-, -C≡C-, -N=N-, -N(R^a)-N(R^a)-, -N(R^a)-C(O)-N(R^a)-, -C(S)-N(R^a)-, -N(R^a)-C(S)-, -CH₂-, -O-CH₂-, -CH₂-O-, -S-CH₂-, or -CH₂-S-.

20 [47] Each R^a is independently selected from the group consisting of hydrogen and alkyl.

[48] R⁵ is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonyloxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent is, 25 in turn, optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[49] This invention also is directed, in part, to a method for treating a condition mediated by pathological p38 kinase activity (particularly p38α activity) in a mammal. 30 The method comprises administering an above-described compound, tautomer, or salt to the mammal in an amount that is therapeutically-effective to treat the condition.

[50] This invention also is directed, in part, to a method for treating a condition mediated by pathological TNF activity (particularly TNF- α activity) in a mammal. The method comprises administering an above-described compound, tautomer, or salt to the mammal in an amount that is therapeutically-effective to treat the condition.

5 [51] This invention also is directed, in part, to a method for treating a condition mediated by pathological cyclooxygenase-2 activity in a mammal. The method comprises administering an above-described compound, tautomer, or salt to the mammal in an amount that is therapeutically-effective to treat the condition.

[52] This invention also is directed, in part, to pharmaceutical compositions
10 comprising a therapeutically-effective amount of an above-described compound, tautomer, or salt.

[53] This invention also is directed, in part, to a use of an above-described compound, tautomer, or salt to prepare a medicament for treating a condition mediated by p38 kinase activity.

15 [54] This invention also is directed, in part, to a use of an above-described compound, tautomer, or salt to prepare a medicament for treating a condition mediated by TNF activity.

[55] This invention also is directed, in part, to a use of an above-described compound, tautomer, or salt to prepare a medicament for treating a condition mediated by
20 cyclooxygenase-2 activity.

[56] Further benefits of Applicants' invention will be apparent to one skilled in the art from reading this specification.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


25 [57] This detailed description of preferred embodiments is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This detailed description and its specific examples, while indicating preferred embodiments of
30 this invention, are intended for purposes of illustration only. This invention, therefore, is

not limited to the preferred embodiments described in this specification, and may be variously modified.

A. Compounds of This Invention

5 [58] In accordance with this invention, it has been found that certain pyrazole compounds tend to be effective for inhibiting the activity (particularly pathological activity) of p38 kinase, TNF, and/or cyclooxygenase-2. Such compounds tend to exhibit desirable safety profiles, solubilities, and/or potencies.

10 [59] As noted above, the compounds of this invention generally have a structure corresponding to Formula I:



L^1 , L^2 , X^1 , X^2 , X^3 , X^4 , X^5 , X^6 , R^1 , R^{3A} , R^{3B} , R^{3C} , R^4 , and R^5 are defined as follows:

General Description of Preferred L^1 Substituents

15 [60] L^1 is a bond, -O-, -S-, -S(O)-, -S(O)₂-, -N(R^a)-, -C(O)-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -C(O)-O-, -O-C(O)-, -O-C(O)-O-, -C(H)=C(H)-, -C≡C-, -N=N-, -N(R^a)-N(R^a)-, -N(R^a)-C(O)-N(R^a)-, -C(S)-N(R^a)-, -N(R^a)-C(S)-, -CH₂-, -O-CH₂-, -CH₂-O-, -S-CH₂-, or -CH₂-S-.

[61] In some preferred embodiments, L^1 is a bond.

20 [62] Each R^a is independently selected from the group consisting of hydrogen and alkyl

[63] In some preferred embodiments, each R^a is alkyl.

[64] In some preferred embodiments, each R^a is hydrogen.

25 *General Description of Preferred X^1 , X^2 , X^3 , X^4 , X^5 , and X^6 Substituents*


[65] X^1 is nitrogen or carbon bonded to hydrogen, except that X^1 is carbon bonded to hydrogen if any of X^2 , X^3 , X^5 , or X^6 is -NH- or -O-. X^2 is -CH₂-, -NH-, or -O-,

except that X^2 is $-\text{CH}_2-$ if X^3 is $-\text{O}-$ or $-\text{NH}-$. X^3 is $-\text{CH}_2-$, $-\text{NH}-$, or $-\text{O}-$, except that X^3 is $-\text{CH}_2-$ if X^2 is $-\text{O}-$ or $-\text{NH}-$. X^4 is nitrogen or carbon bonded to hydrogen. X^5 is $-\text{CH}_2-$ or $-\text{NH}-$, except that X^5 is $-\text{CH}_2-$ if X^3 is $-\text{O}-$ or X^6 is $-\text{NH}-$. And X^6 is $-\text{CH}_2-$ or $-\text{NH}-$, except that X^6 is $-\text{CH}_2-$ if X^2 is $-\text{O}-$ or X^5 is $-\text{NH}-$.


5 [66] In some preferred embodiments, X^2 , X^3 , X^5 , and X^6 are each $-\text{CH}_2-$.

[67] In some preferred embodiments, X^1 and X^4 are each carbon bonded to hydrogen.


[68] In some preferred embodiments, the ring formed by X^1 , X^2 , X^3 , X^4 , X^5 , and X^6 is cyclohexyl. In such embodiments, X^2 , X^3 , X^5 , and X^6 are each $-\text{CH}_2-$; and X^1 and X^4 are each carbon bonded to hydrogen. In other words, the compound corresponds in
10 structure to the following general formula:




In some preferred embodiments, the compound has a cis configuration with respect to the cyclohexyl group:




In typically more preferred embodiments, the compound has a trans configuration with respect to the cyclohexyl group:




[69] In some preferred embodiments, the ring formed by X^1 , X^2 , X^3 , X^4 , X^5 , and X^6 is piperidinyl. In some such embodiments, it is particularly preferred for X^2 , X^3 , X^5 , and X^6 to each be $-CH_2-$; X^1 to be nitrogen; and X^4 to be carbon bonded to hydrogen. In other words, the compound corresponds in structure to the following general formula:



In other embodiments wherein the ring formed by X^1 , X^2 , X^3 , X^4 , X^5 , and X^6 is piperidinyl, it is particularly preferred for X^2 , X^3 , X^5 , and X^6 to each be $-CH_2-$; X^1 to be carbon bonded to hydrogen; and X^4 to be nitrogen. In other words, the compound corresponds in structure to the following general formula:



[70] In some preferred embodiments, the ring formed by X^1 , X^2 , X^3 , X^4 , X^5 , and X^6 is piperazinyl. In some such embodiments, it is particularly preferred for X^2 , X^3 , X^5 , and X^6 to each be $-CH_2-$; and X^1 and X^4 to each be nitrogen. In other words, the compound corresponds in structure to the following general formula:



General Description of Preferred R¹ Substituents

[71] R¹ is hydrogen, hydroxyalkyl, carboxyalkyl, aminoalkyl, aminocarbonylalkyl, or aminocarbonylaminoalkyl. The amino nitrogen(s) of the aminoalkyl, aminocarbonylalkyl, or aminocarbonylaminoalkyl optionally is/are substituted
5 with up to two independently selected alkyl.

[72] In some preferred embodiments, R¹ is hydrogen.


[73] In some preferred embodiments, R¹ is a non-hydrogen substituent that enhances solubility of the compound relative to the solubility of the compound if R¹ is hydrogen. One such particularly preferred R¹ substituent for enhancing solubility is
10 hydroxyalkyl.

General Description of Preferred R^{3A} and R^{3B} Substituents


[74] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl. Any carbon of
15 the alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[75] In some preferred embodiments, R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of
20 the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.


[76] In some preferred embodiments, R^{3A} is at the ortho position of the 3-position phenyl ring in Formula I, *i.e.*, the compound corresponds in structure to the
25 following formula:



[77] In some preferred embodiments, R^{3A} is at the meta position of the 3-position phenyl ring in Formula I, *i.e.*, the compound corresponds in structure to the following formula:



5 [78] In some preferred embodiments, R^{3A} is at the para position of the 3-position phenyl ring in Formula I, *i.e.*, the compound corresponds in structure to the following formula:



[79] In some preferred embodiments, R^{3A} is hydroxy, cyano, amino, monomethylamino, monoethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, methyl, ethyl, haloethyl, propyl, halopropyl, aminomethyl, aminoethyl, hydroxymethyl, hydroxyethyl, methoxy, halomethoxy, ethoxy, haloethoxy, methoxymethyl, or halomethoxymethyl.

15 [80] In some preferred embodiments, R^{3A} is hydroxy, cyano, amino, monomethylamino, monoethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, methyl, ethyl, haloethyl, propyl, halopropyl, aminomethyl, aminoethyl, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, haloethoxy, methoxymethyl, or halomethoxymethyl.

20 [81] In some preferred embodiments, R^{3A} is halogen, methyl, methoxy, halomethyl, or halomethoxy.

[82] In some preferred embodiments, R^{3A} is chloro, chloromethyl, or chloromethoxy.

[83] In some preferred embodiments, R^{3A} is fluoro, fluoromethyl, or fluoromethoxy.

5 [84] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

10 [85] In some preferred embodiments, R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

15 [86] In some preferred embodiments, R^{3B} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

20 [87] In some preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, chloro, methyl, trifluoromethyl, ethyl, hydroxy, methoxy, trifluoromethoxy, amino, monomethylamino, and dimethylamino.

[88] In some preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of halogen, methyl, methoxy, halomethyl, and halomethoxy.

25 [89] In some preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, fluoro, methyl, methoxy, chloromethyl, fluoromethyl, chloromethoxy, and fluoromethoxy.

[90] In some preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, methyl, methoxy, chloromethyl, and chloromethoxy.

30 [91] In some preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, methyl, methoxy, fluoromethyl, and fluoromethoxy.

[92] In some preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, chloromethyl, and chloromethoxy.


[93] In some preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, fluoromethyl, and fluoromethoxy.

5 [94] In some embodiments, R^{3A} is halogen or haloalkyl; and R^{3B} is hydrogen, halogen, or haloalkyl.


General Description of Preferred R^{3C} Substituents

[95] R^{3C} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl,
10 monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.


[96] In some preferred embodiments, R^{3C} is hydrogen. In other words, the
15 compound corresponds in structure to the following formula:



In some such embodiments, for example, the compound corresponds in structure to the following formula:




20 In other such embodiments, for example, the compound corresponds in structure to the following formula:




(I-L).

In other such embodiments, for example, the compound corresponds in structure to the following formula:




(I-M).

- 5 In other such embodiments, for example, the compound corresponds in structure to the following formula:




(I-N).

In other such embodiments, for example, the compound corresponds in structure to the following formula:



(I-O).

In other such embodiments, for example, the compound corresponds in structure to the following formula:



General Description of Preferred R⁴ Substituents

[97] R⁴ is pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclylloxy, carbocyclylalkoxy, carbocyclylloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocyclylloxy, heterocyclylalkoxy, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocyclylloxycarbonyl, heterocyclylloxycarbonyl, alkoxycarbonylamino, alkoxycarbocyclylamino, alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl. Any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano,

alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

[98] In some such preferred embodiments, R⁴ is pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted as discussed above.

[99] In some such preferred embodiments, R⁴ is pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted as discussed above.

[100] In some such preferred embodiments, R⁴ is pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, maleimidyl, pyridonyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted as discussed above.

[101] In some such preferred embodiments, R⁴ is pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted as discussed above.

[102] In some such preferred embodiments, R⁴ is a 6-member, nitrogen-containing ring that is optionally substituted as discussed above.

[103] In some such preferred embodiments, R⁴ is pyrimidinyl or pyridinyl. The pyrimidinyl or pyridinyl optionally is substituted as discussed above.

[104] In some such preferred embodiments, R⁴ is pyridinyl optionally substituted as discussed above.

[105] In some such preferred embodiments, R⁴ is pyrimidinyl optionally substituted as discussed above.

[106] In some such preferred embodiments, R⁴ is pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted with alkylthio, mono-alkylamino, di-alkylamino, alkoxy, or haloalkoxy.

[107] In some such preferred embodiments, R⁴ is pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl.

[108] In some preferred embodiments, R⁴ is pyrimidinyl optionally substituted with halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclylloxy, carbocyclylalkoxy, carbocyclylloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocyclylloxy, heterocyclylalkoxy, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocyclylloxycarbonyl, heterocyclylloxycarbonyl, alkoxycarbonylamino, alkoxycarbocyclylamino, alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, or carbocyclylhydrazinyl. Any such optional substituent is, in turn,

optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclalkoxy.

5 [109] In some preferred embodiments, R⁴ is pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrynyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. These ring structures are:

10 substituted with one or more substituents independently selected from the group consisting of heterocycloxy, heterocyclalkoxy, cycloalkylamino, cyanoaryloxy, alkylaminoalkylamino, and carbocyclalkylheterocyclamino, wherein:

any such substituent is, in turn, optionally substituted with one or
15 more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclalkoxy; and
optionally substituted with one or more substituents independently selected
20 from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclalkyl, carbocyclalkenyl, carbocycloxy, carbocyclalkoxy, carbocycloxyalkyl, carbocyclylthio, carbocyclsulfinyl, carbocyclsulfonyl, heterocyclylthio, heterocyclsulfinyl, heterocyclsulfonyl, carbocyclalkoxy, carbocyclheterocyclyl, heterocyclalkyl, amino, aminoalkyl, alkylamino,
25 alkenylamino, alkynylamino, carbocyclamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocycloxy carbonyl, heterocycloxy carbonyl, carbocyclalkylamino, alkoxycarbonylamino, alkoxycarbocyclamino, alkoxycarbocyclalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino,
30 alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylaminoalkylamino,

alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, heterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl, wherein:

5 any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclyoxy, heterocyclyl, and heterocyclylalkoxy.

10 [110] In some preferred embodiments, R⁴ is pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. In these embodiments, any such substituent is:

15 substituted with one or more substituents independently selected from the group consisting of heterocyclyoxy, heterocyclylalkoxy, cycloalkylamino, cyanoaryloxy, alkylaminoalkylamino, and carbocyclylalkylheterocyclylamino, wherein:

 any such substituent is, in turn, optionally substituted with one or
20 more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclyoxy, heterocyclyl, and heterocyclylalkoxy; and
 optionally substituted with one or more substituents independently selected
25 from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclyoxy, carbocyclylalkoxy, carbocyclyoxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy,
30 carbocyclylheterocyclyl, heterocyclylalkyl, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, aminocarbonyl, alkoxy,

alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy,
alkoxycarbonyl, carbocyclyloxy, carbocyclyloxy, heterocyclyloxy, carbocyclylalkylamino, alkoxy-carbonylamino, alkoxy-carbocyclylamino,
alkoxy-carbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino,
5 alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylaminoalkylamino,
alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino,
heterocyclylamino, heterocyclylheterocyclylalkylamino,
alkoxycarbonylheterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino,
hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl, wherein:

10 any such optional substituent is, in turn, optionally substituted with
one or more substituents independently selected from the group consisting
of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto,
amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl,
carbocyclyloxy, heterocyclyl, and heterocyclylalkoxy.

15 [111] In some preferred embodiments, R⁴ is pyrimidinyl. In these embodiments,
the pyrimidinyl is:

substituted with one or more substituents independently selected from the
group consisting of heterocyclyloxy, heterocyclylalkoxy, cycloalkylamino,
cyanoaryloxy, alkylaminoalkylamino, and carbocyclylalkylheterocyclylamino,
20 wherein:

any such substituent optionally is, in turn, substituted with one or
more substituents independently selected from the group consisting of
alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto,
amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl,
25 carbocyclyloxy, heterocyclyl, and heterocyclylalkoxy; and
optionally substituted with one or more substituents independently selected
from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl,
carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl,
carbocyclylalkyl, carbocyclylalkenyl, carbocyclyloxy, carbocyclylalkoxy,
30 carbocyclyloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl,
heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy,

carbocyclylheterocyclyl, heterocyclylalkyl, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocyclyloxycarbonyl, heterocyclyloxycarbonyl, carbocyclylalkylamino, alkoxycarbonylamino, alkoxycarbocyclylamino, alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, heterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl, wherein:

any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclyloxy, heterocyclyl, and heterocyclylalkoxy.

[112] In some preferred embodiments, R^4 is pyrimidinyl substituted with heterocyclyloxy, heterocyclylalkoxy, cycloalkylamino, cyanoaryloxy, alkylaminoalkylamino, or carbocyclylalkylheterocyclylamino. Any such substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclyloxy, heterocyclyl, and heterocyclylalkoxy.

[113] In some preferred embodiments, R^4 is pyrimidinyl substituted with heterocyclyloxy, heterocyclylalkoxy, cycloalkylamino, cyanoaryloxy, dialkylaminoalkylamino, or carbocyclylalkylheterocyclylamino.


[114] In some preferred embodiments, R^4 is pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent is substituted

with alkyl, aminoalkyl, alkoxycarbonyl, carbocycloxy carbonyl, heterocycloxy carbonyl, or alkylaminocarbonyl. Any such substituent, in turn, is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.


[115] In some preferred embodiments, R^4 is pyridinyl substituted with alkyl, aminoalkyl, alkoxycarbonyl, carbocycloxy carbonyl, heterocycloxy carbonyl, or alkylaminocarbonyl. Any such substituent, in turn, is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

[116] In some preferred embodiments, R^4 is pyrimidinyl substituted with alkyl, aminoalkyl, alkoxycarbonyl, carbocycloxy carbonyl, heterocycloxy carbonyl, or alkylaminocarbonyl. Any such substituent, in turn, is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.


[117] In some preferred embodiments, R^4 corresponds in structure to the following formula:




[118] In some preferred embodiments, R^4 corresponds in structure to the following formula:




[119] In some preferred embodiments, R^4 corresponds in structure to the following formula:



5 [120] In some preferred embodiments, R^4 corresponds in structure to the following formula:




[121] In some preferred embodiments, R^4 corresponds in structure to the following formula:



10

Here, two of Y^1 , Y^2 , Y^3 , and Y^4 are each nitrogen, one of Y^1 , Y^2 , Y^3 , and Y^4 is carbon bonded to R^{4s} , and one of Y^1 , Y^2 , Y^3 , and Y^4 is carbon bonded to hydrogen.

[122] In some preferred embodiments, R^4 corresponds in structure to the following formula:



(I-V).

[123] In the above embodiments, R^{4s} may be hydrogen, halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocycliloxy, carbocyclylalkoxy, carbocycliloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocycliloxy, heterocyclylalkoxy, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocycliloxy carbonyl, heterocycliloxy carbonyl, alkoxycarbonylamino, alkoxycarbocyclylamino, alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonyl heterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, or carbocyclylhydrazinyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycliloxy, heterocyclyl, and heterocyclylalkoxy.

[124] In some preferred embodiments, R^{4s} is hydrogen, alkyl, aminoalkyl, alkoxyalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, amino, alkylamino, aminoalkylamino, alkoxyalkylamino, cycloalkylamino, heterocycloalkylamino, heteroarylamino, hydroxy, alkoxy, aminoalkoxy, alkoxyalkoxy, cycloalkyloxy, heterocycloalkyloxy, or heteroaryloxy. Any such substituent optionally is substituted with

one or more substituents independently selected from the group consisting of hydroxy and alkyl.

[125] In some preferred embodiments, R^{4a} is hydrogen, C_1 - C_4 -alkyl, aminopropyl, monomethylaminopropyl, dimethylaminopropyl, hydroxypropyl, methoxypropyl, cyclopentylmethyl, pyrrolidinylmethyl, tetrahydrofuranylmethyl, piperidinylmethyl, tetrahydropyranylmethyl, pyridinylmethyl, C_1 - C_3 -alkylamino, aminoethylamino, monomethylaminoethylamino, dimethylaminoethylamino, hydroxyethylamino, methoxyethylamino, cyclopentylamino, pyrrolidinylamino, tetrahydrofuranylamino, piperidinylamino, tetrahydropyranylamino, pyridinylamino, C_1 - C_3 -alkoxy, aminoethoxy, monomethylaminoethoxy, dimethylaminoethoxy, hydroxyethoxy, methoxyethoxy, cyclopentyloxy, pyrrolidinylloxy, tetrahydrofuranyloxy, piperidinylloxy, tetrahydropyranyloxy, or pyridinylloxy. Any pyrrolidinyl nitrogen or piperidinyl nitrogen optionally is substituted with methyl.

[126] In some preferred embodiments, R^{4a} is C_1 - C_4 -alkyl, aminopropyl, monomethylaminopropyl, dimethylaminopropyl, hydroxypropyl, methoxypropyl, cyclopentylmethyl, pyrrolidinylmethyl, tetrahydrofuranylmethyl, piperidinylmethyl, tetrahydropyranylmethyl, pyridinylmethyl, C_1 - C_3 -alkylamino, aminoethylamino, monomethylaminoethylamino, dimethylaminoethylamino, hydroxyethylamino, methoxyethylamino, cyclopentylamino, pyrrolidinylamino, tetrahydrofuranylamino, piperidinylamino, tetrahydropyranylamino, pyridinylamino, C_1 - C_3 -alkoxy, aminoethoxy, monomethylaminoethoxy, dimethylaminoethoxy, hydroxyethoxy, methoxyethoxy, cyclopentyloxy, pyrrolidinylloxy, tetrahydrofuranyloxy, piperidinylloxy, tetrahydropyranyloxy, or pyridinylloxy. Any pyrrolidinyl nitrogen or piperidinyl nitrogen optionally is substituted with methyl.

[127] In some preferred embodiments, R^{4a} is hydrogen, alkyl, aminoalkyl, alkoxyalkyl, cycloalkylalkyl, arylalkyl, heterocycloalkylalkyl, heteroarylalkyl, amino, alkylamino, aminoalkylamino, alkoxyalkylamino, cycloalkylamino, arylamino, heterocycloalkylamino, heteroarylamino, hydroxy, alkoxy, aminoalkoxy, alkoxyalkoxy, cycloalkyloxy, aryloxy, heterocycloalkyloxy, heteroaryloxy, thiol, alkylthio, cycloalkylthio, arylthio, heterocycloalkylthio, heteroarylthio, aminosulfonyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, heterocycloalkylsulfonyl, or

heteroarylsulfonyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy, cyano, and alkyl.

[128] In some preferred embodiments, R^{4s} is hydrogen, C₁-C₆-alkyl, aminoalkyl, 5 alkoxyalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, aminoalkylamino, alkoxyalkylamino, cycloalkylamino, heterocycloalkylamino, heteroarylamino, hydroxy, C₂-C₆-alkoxy, aminoalkoxy, alkoxyalkoxy, cycloalkyloxy, heterocycloalkyloxy, heteroaryloxy, thiol, C₂-C₆-alkylthio, cycloalkylthio, heterocycloalkylthio, heteroarylthio, aminosulfonyl, C₂-C₆-alkylsulfonyl, cycloalkylsulfonyl, heterocycloalkylsulfonyl, or 10 heteroarylsulfonyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy, cyano, and alkyl.

[129] In some preferred embodiments, R^{4s} is C₁-C₆-alkyl, aminoalkyl, alkoxyalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, aminoalkylamino, 15 alkoxyalkylamino, cycloalkylamino, heterocycloalkylamino, heteroarylamino, hydroxy, C₂-C₆-alkoxy, aminoalkoxy, alkoxyalkoxy, cycloalkyloxy, heterocycloalkyloxy, heteroaryloxy, thiol, C₂-C₆-alkylthio, cycloalkylthio, heterocycloalkylthio, heteroarylthio, aminosulfonyl, C₂-C₆-alkylsulfonyl, cycloalkylsulfonyl, heterocycloalkylsulfonyl, or heteroarylsulfonyl. Any such substituent optionally is substituted with one or more 20 substituents independently selected from the group consisting of hydroxy, cyano, and alkyl.

[130] In some preferred embodiments, R^{4s} is alkyl, aminoalkyl, alkoxycarbonyl, carbocyclyloxycarbonyl, heterocyclyloxycarbonyl, or alkylaminocarbonyl. Any such substituent optionally is substituted with one or more substituents independently selected 25 from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclyloxy, heterocyclyl, and heterocyclylalkoxy.

[131] In some preferred embodiments, R^{4s} is alkoxycarbonyl, carbocyclyloxycarbonyl, or heterocyclyloxycarbonyl. Any such substituent optionally is 30 substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro,

cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

[132] In some preferred embodiments, R^{4s} is alkylaminocarbonyl optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

[133] In some preferred embodiments, R^{4s} is $-CH_2OH$, $-C(CH_3)(H)-OH$, or $-C(CH_3)_2-OH$.

[134] In some preferred embodiments, R^{4s} is aminomethyl. In these embodiments, the amino nitrogen optionally is substituted with up to two substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, haloalkyl, alkylsulfonyl, alkoxyalkyl, and heterocyclyl.

[135] In some preferred embodiments, R^{4s} is hydrogen, alkylthio, mono-alkylamino, di-alkylamino, alkoxy, or haloalkoxy.

[136] In some preferred embodiments, R^{4s} is alkylthio, mono-alkylamino, di-alkylamino, alkoxy, or haloalkoxy.

[137] In some preferred embodiments, R^{4s} is heterocycloxy, heterocyclylalkoxy, cycloalkylamino, cyanoaryloxy, dialkylaminoalkylamino, or carbocyclylalkylheterocyclylamino.

[138] In some preferred embodiments, R^{4s} is tetrahydrofuranyloxy, cyanophenyloxy, morpholinylethyloxy, cyclopentylamino, dimethylaminoethylamino, or phenylmethylpiperidinylamino.

[139] In some preferred embodiments, R^{4s} is alkylaminoalkoxy.

[140] In some preferred embodiments, R^{4s} is dialkylaminoalkoxy.

[141] In some preferred embodiments, R^{4s} is dimethylaminoethoxy.

[142] In some preferred embodiments, R^{4s} is hydrogen.

General Description of Preferred L^2 and R^5 Substituents

[143] L^2 is a bond, $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-N(R^a)-$, $-C(O)-$, $-C(O)-N(R^a)-$, $-N(R^a)-C(O)-$, $-C(O)-O-$, $-O-C(O)-$, $-O-C(O)-O-$, $-C(H)=C(H)-$, $-C\equiv C-$, $-N=N-$,

-N(R^a)-N(R^a)-, -N(R^a)-C(O)-N(R^a)-, -C(S)-N(R^a)-, -N(R^a)-C(S)-, -CH₂-, -O-CH₂-,
-CH₂-O-, -S-CH₂-, or -CH₂-S-.

[144] Each R^a is independently selected from the group consisting of hydrogen and alkyl.

5 [145] In some preferred embodiments, each R^a is hydrogen.

[146] In other preferred embodiments, each R^a is alkyl.

[147] In some preferred embodiments, L² is -O-, -S-, -S(O)-, -S(O)₂-, -N(R^a)-, -C(O)-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -C(O)-O-, -O-C(O)-, -O-C(O)-O-, -C(H)=C(H)-, -C≡C-, -N=N-, -N(R^a)-N(R^a)-, -N(R^a)-C(O)-N(R^a)-, -C(S)-N(R^a)-, -N(R^a)-C(S)-, -CH₂-,
10 -O-CH₂-, -CH₂-O-, -S-CH₂-, or -CH₂-S-.

[148] In some preferred embodiments, L² is a bond, -O-, -S-, -S(O)-, -N(R^a)-, -N(R^a)-C(O)-, -O-C(O)-, -O-C(O)-O-, -C(H)=C(H)-, -C≡C-, -N=N-, -N(R^a)-N(R^a)-, -N(R^a)-C(O)-N(R^a)-, -C(S)-N(R^a)-, -N(R^a)-C(S)-, -CH₂-, -O-CH₂-, -CH₂-O-, -S-CH₂-, or -CH₂-S-.

15 [149] In some preferred embodiments, -L² is -C(O)-.

[150] In some preferred embodiments, -L² is -O-.

[151] In some preferred embodiments, L² is -N(R^a)-.

[152] In some preferred embodiments, L² is a bond.

[153] R⁵ is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[154] In some preferred embodiments, R⁵ is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[155] In some preferred embodiments, R⁵ is hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent optionally is

substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[156] In some preferred embodiments, R^5 is alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[157] In some preferred embodiments, R^5 is hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl.

[158] In some preferred embodiments, R^5 is hydrogen, alkenyl, or alkylcarbonylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkoxy, and haloalkoxy.

[159] In some preferred embodiments, R^5 is alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonyloxyalkyl, or tetrahydrofuranylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy and halogen.

[160] In some preferred embodiments, R^5 is alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, or tetrahydrofuranylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy and halogen.

[161] In some preferred embodiments, R^5 is haloalkyl, hydroxyalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[162] In some preferred embodiments, R^5 is phosphonoxyalkyl, monoalkylphosphonoxyalkyl, dialkylphosphonoxyalkyl, aminoalkylcarbonyloxyalkyl,

monoalkylaminoalkylcarbonyloxyalkyl, dialkylaminoalkylcarbonyloxyalkyl, phenylalkyl substituted with alkylcarbonyloxy, or tetrahydrofuranyl.

[163] In some preferred embodiments, R^5 is hydrogen, alkenyl, or alkylcarbonylalkyl.

5 [164] In some preferred embodiments, R^5 is hydroxyalkyl, *i.e.*, alkyl substituted with one or more hydroxy radicals (often only one hydroxy radical).

[165] In some preferred embodiments, R^5 is C_1 - C_6 -hydroxyalkyl.

[166] In some preferred embodiments, R^5 is hydroxymethyl.

[167] In some preferred embodiments, R^5 is alkylcarbonyloxyalkyl.

10 [168] In some preferred embodiments, R^5 is methylcarbonyloxymethyl.

[169] In some preferred embodiments, R^5 is hydrogen.

[170] In some preferred embodiments, R^5 is heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

15 [171] In some preferred embodiments, R^5 is carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.


[172] In some preferred embodiments, R^5 is substituted methyl. The methyl is
20 substituted with:

two substituents independently selected from the group consisting of hydroxy, alkoxy, hydroxymethyl, hydroxyethyl, alkoxymethyl, alkoxyethyl, tetrahydrofuranyl, and tetrahydrofuranylmethyl, wherein any such substituent is, in turn, optionally substituted with one or more substituents independently selected
25 from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy; or


a substituent selected from the group consisting of alkoxyethoxy, hydroxyethoxy, alkoxypropoxy, and hydroxypropoxy, wherein any such substituent is, in turn, optionally substituted with one or more substituents
30 independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

The methyl optionally is further substituted with hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxyalkyl, carbocyclyl, carbocyclalkyl, heterocyclyl, and heterocyclalkyl. Any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.


[173] In some preferred embodiments, R^5 is a radical corresponding in structure to one of the following formulas:




(I-W-1),



(I-W-2),




(I-W-3), and




(I-W-4).


[174] In some preferred embodiments, $-L^2-R^5$ is a radical corresponding in structure to one of the following formulas:




(I-X-1),




(I-X-2),




(I-X-3),




(I-X-4),




(I-X-5),




(I-X-6),



(I-X-8),




(I-X-9), and




(I-X-10).


[175] In some preferred embodiments, $-L^2-R^5$ is a radical corresponding in structure to one of the following formulas:




(I-Y-1),




(I-Y-2),




(I-Y-3),




(I-Y-4),



(I-Y-5),




(I-Y-6), and



(I-Y-7).

[176] In some preferred embodiments, L^2 is a bond; and R^5 is heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[177] In some preferred embodiments, the compound corresponds in structure to the following formula:



(I-Z).

Here, the ring structure A is a heterocyclyl ring that contains a nitrogen bonded to the cyclohexyl. The heterocyclyl ring is also optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[178] In some preferred embodiments, L^2 is $-N(R^4)-$; and R^5 is alkyl, carbocyclyl, or carbocyclylalkyl. The alkyl, carbocyclyl, or carbocyclylalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[179] In some preferred embodiments, $-L^2-R^5$ is hydroxyalkylcarbonyl, i.e., alkylcarbonyl substituted with one or more hydroxy radicals (often only one hydroxy radical).

[180] In some preferred embodiments, $-L^2-R^5$ is hydroxymethylcarbonyl.

[181] In some preferred embodiments, $-L^2-R^5$ is alkylcarbonyloxyalkylcarbonyl.

[182] In some preferred embodiments, $-L^2-R^5$ is methylcarbonyloxymethylcarbonyl.

[183] In some preferred embodiments, $-L^2-R^5$ is hydroxy.

[184] In some preferred embodiments, $-L^2-R^5$ is hydrogen, methyl, or butyloxycarbonyl.

[185] In some preferred embodiments, $-L^2-R^5$ is hydrogen or alkyl.

Detailed Description of Several Preferred Embodiments

[186] The above discussion describes the compounds of this invention in general terms. The following discussion, in turn, describes in detail several specific preferred and particularly preferred embodiments.

Preferred Embodiment No. 1

[187] In some preferred embodiments:

[188] L^2 is -O-, -S-, -S(O)-, -S(O)₂-, -N(R^a)-, -C(O)-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -C(O)-O-, -O-C(O)-, -O-C(O)-O-, -C(H)=C(H)-, -C≡C-, -N=N-,
 5 -N(R^a)-N(R^a)-, -N(R^a)-C(O)-N(R^a)-, -C(S)-N(R^a)-, -N(R^a)-C(S)-, -CH₂-, -O-CH₂-,
 -CH₂-O-, -S-CH₂-, or -CH₂-S-.

[189] R^{3A} and R^{3B} are independently selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, and alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino,
 10 dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

Particularly Preferred Compounds of Embodiment No. 1

15 [190] In some particularly preferred embodiments, R¹ is hydroxyalkyl.

[191] In some particularly preferred embodiments, R¹ is hydrogen.

[192] In some particularly preferred embodiments, L¹ is a bond.

[193] In some particularly preferred embodiments, R^{3C} is hydrogen.

[194] In some particularly preferred embodiments, X², X³, X⁵, and X⁶ are each
 20 -CH₂-.

[195] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, chloro, methyl, trifluoromethyl, ethyl, hydroxy, methoxy, trifluoromethoxy, amino, monomethylamino, and dimethylamino.

[196] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently
 25 selected from the group consisting of halogen, methyl, methoxy, halomethyl, and halomethoxy.

[197] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, fluoro, methyl, methoxy, chloromethyl, fluoromethyl, chloromethoxy, and fluoromethoxy.


[198] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, methyl, methoxy, chloromethyl, and chloromethoxy.

[199] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, methyl, methoxy, fluoromethyl, and fluoromethoxy.


[200] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, chloromethyl, and chloromethoxy.

[201] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, fluoromethyl, and fluoromethoxy.


[202] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[203] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[204] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[205] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




5 [206] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



[207] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[208] In some particularly preferred embodiments, X^1 and X^4 are each carbon bonded to hydrogen. In some such embodiments, the compound corresponds in structure to the following formula:




5

Examples of such compounds include those corresponding in structure to the following formulas:





and



In some embodiments, the preferred geometrical isomers have the trans configuration with respect to the cyclohexyl group. Thus, for example, the preferred geometrical isomers of the compounds of Formulas (27-1) and (27-2) are the following, respectively:


10



[209] In some particularly preferred embodiments, -L² is -C(O)-.

[210] In some particularly preferred embodiments, R⁴ is pyrimidinyl optionally substituted with halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclylloxy, carbocyclylalkoxy, carbocyclylloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocyclylloxy, heterocyclylalkoxy, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxy carbonyl, carbocyclylloxycarbonyl, heterocyclylloxycarbonyl, alkoxy carbonylamino, alkoxy carbocyclylamino, alkoxy carbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxy carbonyl heterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, or carbocyclylhydrazinyl. Any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclylloxy, heterocyclyl, and heterocyclylalkoxy.

[211] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



[212] In some such embodiments, R^{4s} is hydrogen, alkyl, aminoalkyl, alkoxyalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, amino, alkylamino, aminoalkylamino, alkoxyalkylamino, cycloalkylamino, heterocycloalkylamino, heteroarylamino, hydroxy, alkoxy, aminoalkoxy, alkoxyalkoxy, cycloalkyloxy, heterocycloalkyloxy, or heteroaryloxy. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy and alkyl.

[213] In other such embodiments, R^{4s} is hydrogen, C_1 - C_4 -alkyl, aminopropyl, monomethylaminopropyl, dimethylaminopropyl, hydroxypropyl, methoxypropyl, cyclopentylmethyl, pyrrolidinylmethyl, tetrahydrofuranylmethyl, piperidinylmethyl, tetrahydropyranylmethyl, pyridinylmethyl, C_1 - C_3 -alkylamino, aminoethylamino, monomethylaminoethylamino, dimethylaminoethylamino, hydroxyethylamino, methoxyethylamino, cyclopentylamino, pyrrolidinylamino, tetrahydrofuranylamino, piperidinylamino, tetrahydropyranylamino, pyridinylamino, C_1 - C_3 -alkoxy, aminoethoxy, monomethylaminoethoxy, dimethylaminoethoxy, hydroxyethoxy, methoxyethoxy, cyclopentyloxy, pyrrolidinylloxy, tetrahydrofuranyloxy, piperidinylloxy, tetrahydropyranyloxy, or pyridinylloxy. Any pyrrolidinyl nitrogen or piperidinyl nitrogen optionally is substituted with methyl.


[214] In some particularly preferred embodiments, R^4 is pyridinyl, pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent is

substituted with alkyl, aminoalkyl, alkoxycarbonyl, carbocyclooxycarbonyl, heterocyclooxycarbonyl, or alkylaminocarbonyl. Any such substituent, in turn, is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, 5 nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

[215] In some particularly preferred embodiments, R^4 is pyridinyl substituted with alkyl, aminoalkyl, alkoxycarbonyl, carbocyclooxycarbonyl, heterocyclooxycarbonyl, or alkylaminocarbonyl. Any such substituent, in turn, is 10 optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

[216] In some particularly preferred embodiments, R^4 is pyrimidinyl substituted 15 with alkyl, aminoalkyl, alkoxycarbonyl, carbocyclooxycarbonyl, heterocyclooxycarbonyl, or alkylaminocarbonyl. Any such substituent, in turn, is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, 20 heterocyclyl, and heterocyclylalkoxy.

[217] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



In these embodiments, R^{4s} is alkyl, aminoalkyl, alkoxycarbonyl, carbocyclooxycarbonyl, 25 heterocyclooxycarbonyl, or alkylaminocarbonyl. Any such substituent optionally is

substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

5 [218] In some such embodiments, R^{4s} is alkoxycarbonyl, carbocycloxy carbonyl, or heterocycloxy carbonyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl,
10 and heterocyclylalkoxy.


 [219] In some other such embodiments, R^{4s} is alkylaminocarbonyl optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl,
15 and heterocyclylalkoxy.

 [220] In some other such embodiments, R^{4s} is $-CH_2OH$, $-C(CH_3)(H)-OH$, or $-C(CH_3)_2-OH$.

 [221] In some other such embodiments, R^{4s} is aminomethyl. In these embodiments, the amino nitrogen optionally is substituted with up to two substituents
20 independently selected from the group consisting of alkyl, alkenyl, hydroxy, haloalkyl, alkylsulfonyl, alkoxyalkyl, and heterocyclyl.

 [222] In some particularly preferred embodiments, R^5 is alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonyloxyalkyl, or tetrahydrofuranylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected
25 from the group consisting of hydroxy and halogen.


 [223] In some particularly preferred embodiments, $-L^2-R^5$ is a radical corresponding in structure to one of the following formulas:




[224] In some particularly preferred embodiments, $-L^2-R^5$ is hydroxyalkylcarbonyl.

[225] In some particularly preferred embodiments, $-L^2-R^5$ is hydroxymethylcarbonyl.


5 [226] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




Examples of such compounds include those corresponding in structure to the following formulas:




(36-1),



(36-2),




(36-3), and




(36-4).

Additional examples of such compounds include those corresponding in structure to the following formulas:



(36-5), and



(36-6).


In some embodiments, the preferred optical isomer of the compound of Formula (36-5) corresponds in structure to the following formula:



(36-5A).


5

In some embodiments, the preferred optical isomer of the compound of Formula (36-6) corresponds in structure to the following formula:




(36-6A).

[227] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




One such compound, for example, corresponds in structure to the following formula:




5


[228] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




Examples of such compounds include those corresponding in structure to the following
10 formulas:




(40-1),




(40-2),




(40-3),




(40-4),




(40-5),



(40-6),




(40-7), and




(40-8).

Additional examples of such compounds include those corresponding in structure to the following formulas:




(40-9),




(40-10),



(40-11),




(40-12), and



(40-13).


[229] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




(42-1).

Examples of such compounds include those corresponding in structure to the following


5 formulas:




(43-1),



(43-2),




(43-3), and




(43-4).


Examples of such compounds also include those corresponding in structure to the following formulas:



(43-5),




(43-6), and




(43-7).

An additional example of such compounds includes the compound corresponding in structure to the following formula:




(44-1).


An additional example of such compounds includes the compound corresponding in structure to the following formula:




5 An additional example of such compounds includes the compound corresponding in structure to the following formula:




In some embodiments, this compound corresponds in structure to the following optical isomer:






10 In other embodiments, the compound corresponds in structure to the following optical isomer:





[230] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




Examples of such compounds include those corresponding in structure to the following formulas:




Additional examples of such compounds include those corresponding in structure to the following formulas:




In some embodiments, the preferred optical isomer of the compound of Formulas (48-4) corresponds in structure to the following formula:





In some embodiments, the preferred optical isomer of the compound of Formulas (48-5) corresponds in structure to the following formula:




- 5 [231] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




Examples of such compounds include those corresponding in structure to the following formulas:






(50-3), and




(50-4).

Other examples of such compounds include those corresponding in structure to the following formulas:




(50-5), and




(50-6).

In some embodiments, the preferred optical isomer of the compound of Formula (50-5) corresponds in structure to the following formula:



(50-5A).


In some embodiments, the preferred optical isomer of the compound of Formula (50-6) corresponds in structure to the following formula:



(50-5B).

In some embodiments, the preferred isomer of the compound of Formula (50-6)

corresponds in structure to the following formula:



Preferred Embodiment No. 2

[232] In some preferred embodiments:

- 5 [233] R^{3A} and R^{3B} are independently selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, and alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, cycloalkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.
- 10

- [234] R^4 is pyrimidinyl, maleimidyl, pyridonyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any
- 15 such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclylloxy, carbocyclylalkoxy, carbocyclylloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl,
- 20 heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocyclylloxy, heterocyclylalkoxy, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocyclylloxycarbonyl,
- 25 heterocyclylloxycarbonyl, alkoxycarbonylamino, alkoxycarbocyclylamino, alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino,

carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl. Any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycliloxy, heterocyclyl, and heterocyclylalkoxy.

10

Particularly Preferred Compounds of Embodiment No. 2

[235] In some particularly preferred embodiments, R^1 is hydrogen.

[236] In some particularly preferred embodiments, L^1 is a bond.

[237] In some particularly preferred embodiments, R^{3C} is hydrogen.

15 [238] In some particularly preferred embodiments, X^2 , X^3 , X^5 , and X^6 are each $-CH_2-$.

[239] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, and alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

20

[240] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of halogen, methyl, methoxy, halomethyl, and halomethoxy.

25

[241] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, fluoro, methyl, methoxy, chloromethyl, fluoromethyl, chloromethoxy, and fluoromethoxy.

[242] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, methyl, methoxy, chloromethyl, and chloromethoxy.

30


[243] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, methyl, methoxy, fluoromethyl, and fluoromethoxy.

[244] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, chloromethyl, and chloromethoxy.

[245] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, fluoromethyl, and fluoromethoxy.

In some particularly preferred embodiments, R^4 is pyrimidinyl substituted with alkyl, aminoalkyl, alkoxycarbonyl, carbocycloxyloxy, heterocycloxyloxy, or alkylaminocarbonyl. Any such substituent, in turn, is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxyloxy, heterocyclyl, and heterocyclylalkoxy.

[246] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



In these embodiments, R^{4s} is alkyl, aminoalkyl, alkoxycarbonyl, carbocycloxyloxy, heterocycloxyloxy, or alkylaminocarbonyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxyloxy, heterocyclyl, and heterocyclylalkoxy.

[247] In some such embodiments, R^{4s} is alkoxycarbonyl, carbocycloxyloxy, or heterocycloxyloxy. Any such substituent optionally is


substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.

5 [248] In some other such embodiments, R^{4s} is alkylaminocarbonyl optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocycloxy, heterocyclyl, and heterocyclylalkoxy.


10 [249] In some other such embodiments, R^{4s} is $-CH_2OH$, $-C(CH_3)(H)-OH$, or $-C(CH_3)_2-OH$.

15 [250] In some other such embodiments, R^{4s} is aminomethyl. In these embodiments, the amino nitrogen optionally is substituted with up to two substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, haloalkyl, alkylsulfonyl, alkoxyalkyl, and heterocyclyl.


[251] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:





20 [252] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[253] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




- 5 Examples of such compounds include, for example, those corresponding in structure to the following formulas:






(65-3),




(65-4), and




(65-5).

[254] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




(66-1).


Examples of such compounds include, for example, those corresponding in structure to the following formulas:




(67-1),




(67-2),



(67-3),




(67-4), and




(67-5).

Another such compound, for example, corresponds in structure to the following formula:




(67-6).

[255] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



[256] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[257] In some particularly preferred embodiments, $-L^2-R^5$ is hydrogen, methyl, or butyloxycarbonyl.

[258] In some particularly preferred embodiments, $-L^2-R^5$ is hydrogen or alkyl.

Preferred Embodiment No. 3

[259] In some preferred embodiments, the compound corresponds in structure to the following formula:



Here, R^{3A} and R^{3B} are independently selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, and

alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

5 *Particularly Preferred Compounds of Embodiment No. 3*

[260] In some particularly preferred embodiments, R^1 is hydroxyalkyl.

[261] In some particularly preferred embodiments, R^1 is hydrogen.

[262] In some particularly preferred embodiments, L^1 is a bond.

[263] In some particularly preferred embodiments, R^{3C} is hydrogen.

10 [264] In some particularly preferred embodiments, R^{3A} is halogen, methyl, methoxy, halomethyl, or halomethoxy.

[265] In some particularly preferred embodiments, R^{3A} is chloro, chloromethyl, or chloromethoxy.

15 [266] In some particularly preferred embodiments, R^{3A} is fluoro, fluoromethyl, or fluoromethoxy.

[267] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of halogen, methyl, methoxy, halomethyl, and halomethoxy.

20 [268] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, fluoro, methyl, methoxy, chloromethyl, fluoromethyl, chloromethoxy, and fluoromethoxy.

[269] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, methyl, methoxy, chloromethyl, and chloromethoxy.


25 [270] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, methyl, methoxy, fluoromethyl, and fluoromethoxy.

[271] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of chloro, chloromethyl, and chloromethoxy.

30 [272] In some particularly preferred embodiments, R^{3A} and R^{3B} are independently selected from the group consisting of fluoro, fluoromethyl, and fluoromethoxy.


[273] In some particularly preferred embodiments, X^2 , X^3 , X^5 , and X^6 are each $-CH_2-$.

[274] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




5


[275] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



10 [276] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



[277] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



[278] In some particularly preferred embodiments, $-L^2-R^5$ is hydrogen, methyl, or butyloxycarbonyl.

5 *Preferred Embodiment No. 4*

[279] In some preferred embodiments:

[280] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[281] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[282] R^4 is pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclylloxy, carbocyclylalkoxy, carbocyclylloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio,


heterocyclisulfinyl, heterocyclisulfonyl, carbocyclialkoxo, carbocycliheterocyclyl, heterocyclialkyl, heterocyclyloxy, heterocyclialkoxo, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocycliamino, heterocycliamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, 5 alkoxy carbonyl, carbocyclioxy carbonyl, heterocyclioxy carbonyl, alkoxy carbonylamino, alkoxy carbocycliamino, alkoxy carbocyclialkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclialkylamino, alkylaminoalkylaminoalkylamino, alkylheterocycliamino, heterocyclialkylamino, alkylheterocyclialkylamino, 10 carbocyclialkylheterocycliamino, heterocycliheterocyclialkylamino, alkoxy carbonyl heterocycliamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclihydrazinyl. Any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, 15 nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclioxy, heterocyclyl, and heterocyclialkoxo.

Particularly Preferred Compounds of Embodiment No. 4


- [283] In some particularly preferred embodiments, R^1 is hydroxyalkyl.
- 20 [284] In some particularly preferred embodiments, R^1 is hydrogen.
- [285] In some particularly preferred embodiments, L^1 is a bond.
- [286] In some particularly preferred embodiments, R^{3C} is hydrogen.
- [287] In some particularly preferred embodiments, X^2 , X^3 , X^5 , and X^6 are each -CH₂-.
- 25 [288] In some particularly preferred embodiments, -L² is -C(O)-.
- [289] In some particularly preferred embodiments, -L² is -O-.
- [290] In some particularly preferred embodiments, R^5 is alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, or tetrahydrofuranylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting 30 of hydroxy and halogen.

[291] In some particularly preferred embodiments, R^5 is hydrogen, alkenyl, or alkylcarbonylalkyl.


[292] In some particularly preferred embodiments, $-L^2-R^5$ corresponds in structure to one of the following formulas:




(81-1),




(81-2),




(81-3),




(81-4),



(81-5),




(81-6), and



(81-7).


5 [293] In some particularly preferred embodiments, $-L^2-R^5$ is alkylcarbonyl substituted with one or more hydroxy.

[294] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




(83-1).


10 [295] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[296] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



5 [297] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[298] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




10

[299] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



[300] In some particularly preferred embodiments, L^2 is a bond; and R^5 is heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.


[301] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



Here, the ring structure A is a heterocyclyl ring containing a nitrogen bonded to the cyclohexyl. The heterocyclyl ring also is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.


[302] In some particularly preferred embodiments, L^2 is $-N(R^a)-$; and R^5 is alkyl, carbocyclyl, or carbocyclylalkyl. The alkyl, carbocyclyl, or carbocyclylalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

[303] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[304] In some such particularly preferred embodiments, R^{4s} is hydrogen, alkylthio, mono-alkylamino, di-alkylamino, alkoxy, or haloalkoxy.


[305] In some particularly preferred embodiments, the compound corresponds in
5 structure to the following formula:




In some such embodiments, the compound corresponds in structure to the following formula:







10 One such compound, for example, corresponds in structure to the following formula:




[306] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




- 5 Here, two of Y¹, Y², Y³, and Y⁴ are each nitrogen, one of Y¹, Y², Y³, and Y⁴ is carbon bonded to R^{4s}, and one of Y¹, Y², Y³, and Y⁴ is carbon bonded to hydrogen. In some such embodiments, the compound corresponds in structure to one of the following formulas:




In such embodiments, for example, the compound corresponds in structure to one of the following formulas:




(102-1),



(102-2),




(102-3), and




(102-4).

[307] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




(103-1).

In some such embodiments, the compound corresponds in structure to the following
5 formula:



(104-1).


These embodiments include, for example, compounds corresponding in structure to the following formula:



(106-1).

Preferred Embodiment No. 5

[308] In some preferred embodiments, the compound corresponds in structure to
 5 the following formula:



(107-1).

Here:

[309] R^{3A} is hydroxy, cyano, amino, monomethylamino, monoethylamino, dimethylamino, diethylamino, N-methyl-N-ethyl-amino, methyl, ethyl, haloethyl, propyl, halopropyl, aminomethyl, aminoethyl, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, haloethoxy, methoxymethyl, or halomethoxymethyl.
 10


[310] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is
 15 substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[311] R^5 is hydroxyalkyl.


Particularly Preferred Compounds of Embodiment No. 5

- [312] In some particularly preferred embodiments, R^1 is hydroxyalkyl.
- [313] In some particularly preferred embodiments, R^1 is hydrogen.
- [314] In some particularly preferred embodiments, R^{3C} is hydrogen.
- 5 [315] In some particularly preferred embodiments, R^{4s} is hydrogen.
- [316] In some particularly preferred embodiments, R^5 is C_1 - C_6 -hydroxyalkyl.
- [317] In some particularly preferred embodiments, R^5 is hydroxymethyl.


Examples of such compounds include, for example, those corresponding in structure to the following formulas:



(109-1),



(109-2), and




(109-3).

10

Preferred Embodiment No. 6

- [318] In some preferred embodiments, the compound corresponds in structure to the following formula:



(110-1).

Here:

[319] R^{3A} is hydroxy, cyano, amino, monomethylamino, monoethylamino, dimethylamino, diethylamino, N-methyl-N-ethyl-amino, methyl, ethyl, haloethyl, propyl, halopropyl, aminomethyl, aminoethyl, hydroxymethyl, hydroxyethyl, methoxy, halomethoxy, ethoxy, haloethoxy, methoxymethyl, or halomethoxymethyl.

[320] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[321] R^5 is hydroxyalkyl.

Particularly Preferred Compounds of Embodiment No. 6

[322] In some particularly preferred embodiments, R^1 is hydroxyalkyl.

[323] In some particularly preferred embodiments, R^1 is hydrogen.


[324] In some particularly preferred embodiments, R^{3C} is hydrogen.

[325] In some particularly preferred embodiments, R^{4s} is hydrogen.

[326] In some particularly preferred embodiments, R^5 is C_1 - C_6 -hydroxyalkyl.


[327] In some particularly preferred embodiments, R^5 is hydroxymethyl.

[328] Examples of particularly preferred compounds include those corresponding in structure to the following formulas:



Preferred Embodiment No. 7

[329] In some preferred embodiments, the compound corresponds in structure to the following formula:



5 Here:

[330] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[331] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[332] R^5 is phosphonoxyalkyl, monoalkylphosphonoxyalkyl, dialkylphosphonoxyalkyl, aminoalkylcarbonyloxyalkyl, monoalkylaminoalkylcarbonyloxyalkyl, dialkylaminoalkylcarbonyloxyalkyl, phenylalkyl substituted with alkylcarbonyloxy, or tetrahydrofuranyl.

20

Particularly Preferred Compounds of Embodiment No. 7


[333] In some particularly preferred embodiments, R^1 is hydroxyalkyl.

[334] In some particularly preferred embodiments, R^1 is hydrogen.


[335] In some particularly preferred embodiments, R^{3C} is hydrogen.

[336] In some particularly preferred embodiments, R⁴⁸ is hydrogen.


[337] Examples of particularly preferred compounds include those corresponding in structure to the following formulas:




(114-1),




(114-2),




(114-3),



(114-4),




(114-5), and



(114-6).

In some embodiments, the preferred optical isomer of the compound of Formula (114-6)


5 corresponds in structure to the following formula:



(114-6A).

Preferred Embodiment No. 8

[338] In some preferred embodiments, the compound corresponds in structure to the following formula:



5 Here:

[339] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

10

[340] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

15

[341] R^{4s} is hydrogen, alkyl, aminoalkyl, alkoxyalkyl, cycloalkylalkyl, arylalkyl, heterocycloalkylalkyl, heteroarylalkyl, amino, alkylamino, aminoalkylamino, alkoxyalkylamino, cycloalkylamino, arylamino, heterocycloalkylamino, heteroarylamino, hydroxy, alkoxy, aminoalkoxy, alkoxyalkoxy, cycloalkyloxy, aryloxy, heterocycloalkyloxy, heteroaryloxy, thiol, alkylthio, cycloalkylthio, arylthio, heterocycloalkylthio, heteroarylthio, aminosulfonyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, heterocycloalkylsulfonyl, or heteroarylsulfonyl. Any such substituent

20

optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy, cyano, and alkyl.

[342] R^5 is alkylcarbonyloxyalkyl.

5 *Particularly Preferred Compounds of Embodiment No. 8*

[343] In some particularly preferred embodiments, R^1 is hydroxyalkyl.

[344] In some particularly preferred embodiments, R^1 is hydrogen.


[345] In some particularly preferred embodiments, R^{3C} is hydrogen.

[346] In some particularly preferred embodiments, R^{4s} is hydrogen.

10 [347] In some particularly preferred embodiments, X^1 is carbon bonded to hydrogen.


[348] In some particularly preferred embodiments, L^1 is a bond.

[349] In some particularly preferred embodiments, R^5 is methylcarbonyloxymethyl. Examples of such compounds include those corresponding in
15 structure to the following formulas:



Preferred Embodiment No. 9

[350] In some preferred embodiments, the compound corresponds in structure to the following formula:



5 Here:

[351] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[352] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[353] R^{4s} is hydrogen, C_1 - C_6 -alkyl, aminoalkyl, alkoxyalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, aminoalkylamino, alkoxyalkylamino, cycloalkylamino, heterocycloalkylamino, heteroarylamino, hydroxy, C_2 - C_6 -alkoxy, aminoalkoxy, alkoxyalkoxy, cycloalkyloxy, heterocycloalkyloxy, heteroaryloxy, thiol, C_2 - C_6 -alkylthio, cycloalkylthio, heterocycloalkylthio, heteroarylthio, aminosulfonyl, C_2 - C_6 -alkylsulfonyl, cycloalkylsulfonyl, heterocycloalkylsulfonyl, or heteroarylsulfonyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy, cyano, and alkyl.

[354] R^5 is hydroxyalkyl.

Particularly Preferred Compounds of Embodiment No. 9

[355] In some particularly preferred embodiments, R^1 is hydroxyalkyl.

5 [356] In some particularly preferred embodiments, R^1 is hydrogen.

[357] In some particularly preferred embodiments, R^{3C} is hydrogen.





[358] In some particularly preferred embodiments, R^{4s} is hydrogen.


[359] In some particularly preferred embodiments, X^1 is carbon bonded to hydrogen.

10 [360] In some particularly preferred embodiments, L^1 is a bond.


[361] In some particularly preferred embodiments, R^5 is hydroxymethyl.

Examples of such compounds include those corresponding in structure to the following formulas:







(124-5),




(124-6),



(124-7),




(124-8), and




(124-9).

In some embodiments, the preferred optical isomer of the compound of Formula (124-9) corresponds in structure to the following formula:



(124-9A).

In some embodiments, the preferred optical isomer of the compound of Formula (124-9) corresponds in structure to the following formula:




(124-9B).

5

Preferred Embodiment No. 10

[362] In some preferred embodiments, the compound corresponds in structure to the following formula:



(125-1).

10 Here,

[363] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

15


[364] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[365] R⁴ is pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, tetrazinyl, benzazinyl, benzodiazinyl, naphthyridinyl, pyridopyridinyl, pyrinyl, maleimidyl, pyridonyl, thiazolyl, isothiazolyl, thiazolylalkyl, isothiazolylalkyl, thiazolylamino, isothiazolylamino, thiomorpholinyl, the sulfoxide of thiomorpholinyl, or the sulfone of thiomorpholinyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, thiol, carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclylloxy, carbocyclylalkoxy, carbocyclylloxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocyclylloxy, heterocyclylalkoxy, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocyclylloxycarbonyl, heterocyclylloxycarbonyl, alkoxycarbonylamino, alkoxycarbocyclylamino, alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl. Any such optional substituent is, in turn, optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclylloxy, heterocyclyl, and heterocyclylalkoxy.


- [366] R^5 is hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxy carbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogens, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.

Particularly Preferred Compounds of Embodiment No. 10


- [367] In some particularly preferred embodiments, R^1 is hydroxyalkyl.
 [368] In some particularly preferred embodiments, R^1 is hydrogen.
 10 [369] In some particularly preferred embodiments, R^{3C} is hydrogen.
 [370] In some particularly preferred embodiments, X^1 is carbon bonded to hydrogen.
 [371] In some particularly preferred embodiments, L^1 is a bond.
 [372] In some particularly preferred embodiments, the compound corresponds in
 15 structure to the following formula:




- [373] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:



- 20 [374] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




[375] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




5 [376] In some particularly preferred embodiments, R⁵ is hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl.

10 [377] In some particularly preferred embodiments, R⁵ is hydrogen, alkenyl, or alkylcarbonylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkoxy, and haloalkoxy.


 [378] In some particularly preferred embodiments, the compound corresponds in structure to one of the following formulas:



(132-1),




(132-2), and




(132-3).

In some embodiments, the preferred isomer of the compound of Formula (132-1) corresponds in structure to the following formula:




(132-1A).

In some embodiments, the preferred isomer of the compound of Formula (132-2) corresponds in structure to the following formula:




(132-2A).

In some embodiments, the preferred isomer of the compound of Formula (132-3) corresponds in structure to the following formula:



Preferred Embodiment No. 11

[379] In some preferred embodiments, the compound corresponds in structure to
 5 the following formula:



Here:

[380] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl,
 10 aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.


[381] R^{3B} is hydrogen, halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl,
 15 aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and cyano.

[382] R^4 is pyridinyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, thiol,
 20 carboxy, nitro, alkyl, carboxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylcarbonyl, carbocyclyl, carbocyclylalkyl, carbocyclylalkenyl, carbocyclyoxy, carbocyclylalkoxy, carbocyclyoxyalkyl, carbocyclylthio, carbocyclylsulfinyl, carbocyclylsulfonyl, heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, carbocyclylalkoxy, carbocyclylheterocyclyl, heterocyclylalkyl, heterocyclyoxy, heterocyclylalkoxy, amino,

- aminoalkyl, alkylamino, alkenylamino, alkynylamino, carbocyclylamino, heterocyclylamino, aminocarbonyl, alkoxy, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, carbocyclyloxy carbonyl, heterocyclyloxy carbonyl, alkoxycarbonylamino, alkoxycarbocyclylamino, 5 alkoxycarbocyclylalkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkoxyalkoxy, aminoalkoxy, aminoalkylamino, alkylaminoalkylamino, carbocyclylalkylamino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, carbocyclylalkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, 10 alkylaminocarbonyl, alkylcarbonylamino, hydrazinyl, alkylhydrazinyl, and carbocyclylhydrazinyl. Any such optional substituent optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, hydroxy, halogen, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, carbocyclyloxy, heterocyclyl, and 15 heterocyclylalkoxy.
- [383] R^5 is alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl. Any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, alkyl, 20 haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy.


Particularly Preferred Compounds of Embodiment No. 11

- [384] In some particularly preferred embodiments, R^1 is hydroxyalkyl.
- [385] In some particularly preferred embodiments, R^1 is hydrogen.
- 25 [386] In some particularly preferred embodiments, R^{3C} is hydrogen.
- [387] In some particularly preferred embodiments, X^1 is carbon bonded to hydrogen.
- [388] In some particularly preferred embodiments, L^1 is a bond.
- [389] In some particularly preferred embodiments, the compound corresponds in 30 structure to the following formula:



(134-1).

[390] In some particularly preferred embodiments, the compound corresponds in structure to the following formula:




(135-1).

5

Preferred Embodiment No. 12

[391] In some preferred embodiments, the compound corresponds in structure to the following formula:



(136-1).

10 Here:

[392] R^{3A} is halogen, hydroxy, cyano, amino, alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl. Any carbon of the alkyl, aminoalkyl, monoalkylamino, dialkylamino, alkoxy, or alkoxyalkyl optionally is